Stock Market Reviews

SLNO (Soleno Therapeutics, Inc.) News

Get the latest news, insights, and market updates on SLNO (Soleno Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Soleno Therapeutics, Inc. (SLNO): A Bull Case Theory
  We came across a bullish thesis on Soleno Therapeutics, Inc. on X.com by seedy19tron. In this article, we will summarize the bulls’ thesis on SLNO. Soleno Therapeutics, Inc.’s share was trading at $62.74 as of October 8th. SLNO’s forward P/E was 24.15 according to Yahoo Finance. Soleno Therapeutics (SLNO) is a single-asset company focused on VYKAT XR, […]
  Oct 22, 2025 - $SLNO
• Is Soleno Therapeutics’ Surge Justified After Recent Clinical Trial Progress?
  Trying to decide what to do with Soleno Therapeutics stock right now? You are not alone. Whether you have been tracking the company's extraordinary long-term run or just noticed its latest jump, Soleno has become impossible to ignore. In only the past week, the stock rose 5.6%, and over the past 30 days, it gained an impressive 22.6%. Year-to-date, shares are up 46.9%, while the one-year return sits at 25.1%. The real stunner, though, is the three-year return: a whopping 5,063.8%. Even across...
  Oct 22, 2025 - $SLNO
• Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
  REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provi
  Oct 21, 2025 - $SLNO
• Soleno Therapeutics (SLNO): Evaluating the Stock’s Valuation After Recent Share Price Momentum
  Soleno Therapeutics (SLNO) has shown some eye-catching movement over the past month, with shares climbing close to 20%. Investors are paying attention to what is driving this change and looking for clues about the next steps. See our latest analysis for Soleno Therapeutics. That recent rally in Soleno Therapeutics' share price has attracted plenty of attention, but it comes after a period of volatility. The stock has surged nearly 20% in the last month, recovering some ground after a steeper...
  Oct 21, 2025 - $SLNO
• Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating
  Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best healthcare stocks with the highest upside. Goldman Sachs initiated coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) on October 7 with a Buy rating, assigning the stock a $125 price target. The analyst told investors that Goldman Sachs expects Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) Vykat XR to become a […]
  Oct 18, 2025 - $SLNO
• Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
  Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearl
  Oct 13, 2025 - $SLNO
• Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT
  Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best biotech stocks with high potential. In a report released on October 3, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $145.00. Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported in its fiscal Q2 2025 results that it […]
  Oct 7, 2025 - $SLNO
• Soleno Therapeutics (SLNO): Reassessing Valuation After VYKAT XR Safety Debate and Analyst Support
  Soleno Therapeutics (SLNO) shares have been active lately, catching investor attention after a short-seller report questioned the safety and outlook of its VYKAT XR drug. This was quickly followed by a legal review and supportive analyst commentary. These developments have sparked renewed debate about the company’s future direction. See our latest analysis for Soleno Therapeutics. Soleno Therapeutics’ share price has been on a rollercoaster this year, driven by swings in sentiment from a...
  Oct 7, 2025 - $SLNO
• Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123
  Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, Wells Fargo analyst Derek Archila reiterated a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $123.00. Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported that it used $12.6 million of cash […]
  Sep 30, 2025 - $SLNO
• ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
  Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
  Sep 25, 2025 - $SLNO